Terms: = Breast cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
13266 results:
1. Trastuzumab deruxtecan versus treatment of physician's choice in patients with her2-positive metastatic breast cancer (DESTINY-breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
[TBL] [Abstract] [Full Text] [Related]
2. The use of longitudinal CT-based radiomics and clinicopathological features predicts the pathological complete response of metastasized axillary lymph nodes in breast cancer.
Wang J; Tian C; Zheng BJ; Zhang J; Jiao DC; Qu JR; Liu ZZ
BMC Cancer; 2024 May; 24(1):549. PubMed ID: 38693523
[TBL] [Abstract] [Full Text] [Related]
3. Neoadjuvant Chemotherapy in Patients with her2-Negative breast cancer: A Report from Clinical breast cancer Registry of Iran.
Roudini K; Mirzania M; Yavari T; Seyyedsalehi MS; Nahvijou A; Zebardast J; Saadat M; Khajeh-Mehrizi A
Arch Iran Med; 2024 Apr; 27(4):206-215. PubMed ID: 38685847
[TBL] [Abstract] [Full Text] [Related]
4. Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in her2-positive and her2-negative breast cancer patients.
Thonusin C; Osataphan N; Leemasawat K; Nawara W; Sriwichaiin S; Supakham S; Gunaparn S; Apaijai N; Somwangprasert A; Phrommintikul A; Chattipakorn SC; Chattipakorn N
J Transl Med; 2024 Apr; 22(1):398. PubMed ID: 38685030
[TBL] [Abstract] [Full Text] [Related]
5. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
6. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract] [Full Text] [Related]
7. Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to breast cancer Development.
Pseftogas A; Xanthopoulos K; Siasiaridis A; Poutahidis T; Gonidas C; Tsingotjidou A; Hatzivassiliou E; Mosialos G
Anticancer Res; 2024 May; 44(5):1885-1894. PubMed ID: 38677721
[TBL] [Abstract] [Full Text] [Related]
8. Analysis on status quo and related factors of delays in diagnosis and treatment of breast cancer in Ningxia Hui Autonomous Region.
Wang Y; Bai Z; Liu Q; Yu H; Tang Z; Liu X; Liu Q
Medicine (Baltimore); 2024 Apr; 103(17):e37826. PubMed ID: 38669416
[TBL] [Abstract] [Full Text] [Related]
9. Real-World treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic breast cancer in a Canadian Setting Using AI-Extracted Data.
Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
[TBL] [Abstract] [Full Text] [Related]
11. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated her2-negative metastatic breast cancer.
Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
[TBL] [Abstract] [Full Text] [Related]
12. NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic her2-positive breast cancer.
Jacobs SA; Wang Y; Abraham J; Feng H; Montero AJ; Lipchik C; Finnigan M; Jankowitz RC; Salkeni MA; Maley SK; Puhalla SL; Piette F; Quinn K; Chang K; Nagy RJ; Allegra CJ; Vehec K; Wolmark N; Lucas PC; Srinivasan A; Pogue-Geile KL
Breast Cancer Res; 2024 Apr; 26(1):69. PubMed ID: 38650031
[TBL] [Abstract] [Full Text] [Related]
13. Clustering of HR + /her2- breast cancer in an Asian cohort is driven by immune phenotypes.
Pan JW; Ragu M; Chan WQ; Hasan SN; Islam T; Teoh LY; Jamaris S; See MH; Yip CH; Rajadurai P; Looi LM; Taib NAM; Rueda OM; Caldas C; Chin SF; Lim J; Teo SH
Breast Cancer Res; 2024 Apr; 26(1):67. PubMed ID: 38649964
[TBL] [Abstract] [Full Text] [Related]
14. Human Blood Serum Counteracts EGFR/her2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression.
Shaban N; Raevskiy M; Zakharova G; Shipunova V; Deyev S; Suntsova M; Sorokin M; Buzdin A; Kamashev D
Biochemistry (Mosc); 2024 Mar; 89(3):487-506. PubMed ID: 38648768
[TBL] [Abstract] [Full Text] [Related]
15. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
[TBL] [Abstract] [Full Text] [Related]
16. Inflammatory breast cancer: An overview about the histo-pathological aspect and diagnosis.
Sahraoui G; Rahoui N; Driss M; Mrad K
Int Rev Cell Mol Biol; 2024; 384():47-61. PubMed ID: 38637099
[TBL] [Abstract] [Full Text] [Related]
17. Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With breast cancer.
Bhimani J; O'Connell K; Ergas IJ; Foley M; Gallagher GB; Griggs JJ; Heon N; Kolevska T; Kotsurovskyy Y; Kroenke CH; Laurent CA; Liu R; Nakata KG; Persaud S; Rivera DR; Roh JM; Tabatabai S; Valice E; Bowles EJA; Bandera EV; Kushi LH; Kantor ED
JCO Clin Cancer Inform; 2024 Apr; 8():e2300209. PubMed ID: 38635936
[TBL] [Abstract] [Full Text] [Related]
18. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic breast cancer Treated With Abemaciclib: Data From the SCRUM-Japan cancer Genome Screening Project.
Hattori M; Serelli-Lee V; Naito Y; Yamanaka T; Yasojima H; Nakamura R; Fujisawa T; Imai M; Nakamura Y; Bando H; Kawaguchi T; Yoshino T; Iwata H
JCO Precis Oncol; 2024 Apr; 8():e2300647. PubMed ID: 38635933
[TBL] [Abstract] [Full Text] [Related]
19. Exploring Anticancer Properties of Medicinal Plants against breast cancer by Downregulating Human Epidermal Growth Factor Receptor 2.
Gupta S; Prem R; Sethy C; Shrivastava S; Singh M; Yadav P; Huddar VG; Prajapati PK; Roy A; Sundd M; Patel AK
J Agric Food Chem; 2024 May; 72(17):9717-9734. PubMed ID: 38624258
[TBL] [Abstract] [Full Text] [Related]
20. Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Masuda Y; Yamashita S; Nakayama Y; Shimizu R; Konishi M
Biol Pharm Bull; 2024; 47(4):840-847. PubMed ID: 38616114
[TBL] [Abstract] [Full Text] [Related]
[Next]
